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Susan Greenfield:
from maverick scientist
to media darling
Georgina Ferry
“I never say no to anything,” says the
neuroscientist Susan Greenfield,
“without giving myself time to think
about it.” This openness to new
possibilities perhaps goes some way
towards explaining how someone
who left school with no qualifications
in science is now Britain’s foremost
scientific celebrity. Winner of this
year’s Faraday Award, given by the
Royal Society to the scientist who
has done most to further the public
understanding of science in the UK,
she has also just taken up the post of
Director of the Royal Institution
(RI). This 200-year-old scientific
society holds regular events for
members and the general public at
its imposing establishment in the
heart of London’s West End.
Greenfield’s appointment indicates a
desire on the part of the RI to widen
its appeal to members and non-
members alike.
The RI pioneered efforts to
increase the public’s understanding
of science through its Christmas
Lectures, inaugurated by Michael
Faraday in 1826. Greenfield shot to
public notice when, as a lecturer in
the pharmacology department at
Oxford University, she became the
first woman ever to give the lectures,
which are televised by the BBC. The
lecture series, Journey to the Centres of
the Brain, started a trickle of requests
for media appearances. Journalists
and producers quickly discovered
that Greenfield was a personable and
engaging speaker, who could be
relied on for a soundbite on anything
from young people and drugs to the
nature of human consciousness.
The trickle became a torrent.
Radio and television chat shows,
magazine interviews, public lectures,
a fortnightly column in the
Independent on Sunday (“it allows me
to exercise my bigotry on any topic”),
and a succession of popular books has
meant that she is rarely out of the
public eye. This autumn she will
present a four-part series on drugs, for
national radio, and next year she will
present six one-hour programmes on
the brain for BBC television.
Greenfield has found the
experience hugely enjoyable.
“Scientific papers have to be written
in a very rigid format,” she says.
“Writing for the press is very
different: I enjoy thinking up an
arresting image, using a freer form of
expression, whether I’m sounding off
about science policy, or talking about
the brain.” Commentators such as
Bernard Dixon have applauded the
willingness of Greenfield and others
to participate not only in the
dissemination of science but “its
reintegration into the intellectual life
of our times” (Curr Biol 1997,
7:R396). But such activities continue
to raise eyebrows among the majority
of scientists, who cultivate a
fastidious horror of anything that
smacks of self-promotion.
Greenfield, however, has never
been afraid to seem unconventional.
She did A-levels (High School
exams) in mathematics, Latin, Greek
and ancient history, then went to
Oxford to do a Bachelor’s degree in
experimental psychology. Realising
that she was more interested in the
nuts and bolts of brain function, she
accepted her tutor’s challenge that
she try research, and despite a lack of
lab experience was accepted as a
doctoral student by David Smith in
the Pharmacology Department at
Oxford, in the 1970s. 
After postdoctoral positions in
Paris and New York, she returned to
Oxford and established a lab
exploring the non-cholinergic release
of cholinesterase from neurons. She
found that neurons in the substantia
nigra — the brain region that is
destroyed in Parkinson’s disease —
release cholinesterase from their
dendrites in a manner that is not
related to levels of its normal
substrate, acetylcholine. She has
suggested that cholinesterase has a
neuromodulatory role, which could
have implications for the treatment
of Parkinson’s disease and other
degenerative diseases such as
Alzheimer’s and motor neuron
disease.
Her findings were initially
greeted with some scepticism.
Greenfield freely admits that it is not
the sort of work that readily attracts
funding from the usual public sector
sources, and for much of the past
decade she has been one of the
beneficiaries of the £10 million in
research grants that Bristol–Myers
Squibb awarded the Pharmacology
Department in 1987. Today she feels
the work is gradually gaining
acceptance, as others investigate the
same phenomenon.
In 1997 she felt sufficiently
confident to launch a company,
Synaptica, to take forward the
commercial development of a
peptide that she and a colleague,
David Vaux, have identified as the
key part of the cholinesterase
molecule. The 15 researchers in her
lab are now almost all supported
from the funds raised privately to
launch the company, in which
Oxford University is the largest
single shareholder.
How Greenfield came to accept
the RI job gives a whole new
meaning to the expression ‘having it
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all’. “My immediate worry was that
as Director I would have to give up
research, which has always been my
biggest excitement,” she says. But
she worked out a deal with the RI
and Oxford University which allows
her to keep her lab in Oxford for up
to four years — time enough to
establish whether or not Synaptica
will take off on its own. Unlike
previous Directors, she will not
supervise the research work of the
RI’s own Davy–Faraday Laboratory.
She will concentrate on raising the
public profile of the RI, establishing
it as a centre for thinking about
science, while at the same time
trying to reach a wider audience. And
she will still make the television
series, which commits her to 120
days of filming. 
“You have to remember that I
always get up at 5.00am and work a
12-hour day,” she says. “It’s true
that I do very little at the bench, but
the important thing is the quality of
the time, not the quantity. I often
think that doing so many outside
things has meant that I use my time
more efficiently.” 
If Synaptica fails, Greenfield is
sanguine about the possibility that
she may have burnt her boats as a
research scientist. “I can envisage
the possibility of focusing on my
more theoretical writing on topics
such as consciousness,” she says. “I
could not go back to publicly-
funded, i-dotting, t-crossing work. I
may not qualify by the usual criteria
as a successful mainstream scientist,
but I’m very happy being myself.”
She has learned to live with
colleagues who, while rarely
criticising her to her face, show their
disdain — or jealousy? — by
avoiding any reference to her success
on the public stage. “If the situation
was reversed I’d probably do the
same,” says Greenfield frankly. “It’s
just human nature. This sort of
pursuit is not for people who worry
about that kind of thing.”
Georgina Ferry is a freelance science writer
based in Oxford, UK.
Essay
A manifesto for
microbial genomics
Carl R. Woese
The future of biology lies in
genomics. As the current titanic
struggle over the Human Genome
Project attests, the knowledge and
power inherent in genomics are
staggering. Frankly, I don’t know
whether all this hubbub will
ultimately work to the benefit or
detriment of the Human Genome
Project. But I don’t really care, for it
is clear to me that in the long run
the sequence of the human genome
— despite its vast medical potential
— will not, in itself, make a major
contribution to our understanding of
biology.
The Human Genome Project is
distorting our view of genome
sequencing
What does concern me about the
Human Genome Project, however, is
the way in which it is distorting our
view of genome sequencing, tending
to inhibit the sequencing of other
important genomes, mask the
deeper, more general, reasons for
genome sequencing and suppress an
approach to genome sequencing that
would otherwise benefit a wider
spectrum of biologists.
DNA sequencing initially
followed a natural progression. With
improving techniques, the amount
of data generated per year steadily
increased, more or less at an
exponential pace, and the sizes of
the pieces of DNA sequenced
increased proportionately. Interest in
the budding field grew as the small
viral genomes were sequenced. By
the time the human genome started
to attract attention, large viral
genomes were being sequenced and
the next logical step in the
progression would have been the
sequencing of small bacterial ones.
I remember a conversation I had
with Sydney Brenner in 1982 — on
the occasion of the Darwin
Centenary in Cambridge, UK — in
which he casually said that he was
considering sequencing a third of a
Rhodobacter genome, that is, about
two million base pairs of DNA. I
was stunned that nucleic acid
sequencing had progressed so far, so
fast. The day of bacterial genomics
had arrived — and just in time. The
archaebacteria (as the group was
then called) had been discovered
only five years before, and their
characterization lagged decades
behind that of the eubacteria.
Something drastic like genome
sequencing would be needed to
bring the Archaea up to speed and I
returned to the University of Illinois
with a single purpose: to set up a
microbial genome sequencing
project.
But in the mid-1980s the Human
Genome Project came onto the
scene and began to dominate it.
Those driving the project — and
many other people — saw the
human genome as the ultimate goal
towards which all genome
sequencing was directed, and there
was no need to delay further by
ramping up through the microbial
genomes of various sizes. The major
effort should go into developing the
methodology to sequence the
human genome — which was about
three orders of magnitude too large
for technology to handle at that
stage — and to sequence the
genomes of a few ‘model organisms’
that would be useful in interpreting
it. This, effectively, spelled the end
for any fledgling microbial genome
sequencing projects.
Microbial genomics began to
re-emerge, however, in the mid-1990s,
thanks in large measure to the
microbial genome program instituted
by the US Department of Energy,
which served to break the conceptual
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ice, as it were. The feasibility of, and
ease with which, microbial genomes
could be sequenced was strikingly
demonstrated in 1995 when The
Institute for Genomic Research
published the complete sequence of
the Haemophilus influenzae genome.
In arriving late, microbial
genomics did not arrive tabula rasa
(as it would have, had nucleic acid
sequencing progressed according to
the old paradigm). The Human
Genome Project had set the tone for
all genomics. And such a climate
was, at best, alien for microbial
genomics. Because the human
genome had been rationalized to
science and society in terms of its
medical benefits, from the start
microbial genomes were rationalized
similarly, each for a different specific
practical purpose: medical,
agricultural, industrial, bioremedial,
and so on.
Although goals of this sort are
laudable, and of benefit to microbial
genomics in the short run, it is the
future reasons for selecting
microbial genomes for sequencing
that concern me. Microbial
genomics is potentially a far richer,
deeper discipline than
rationalizations such as these would
suggest. Rationales for sequencing
microbial genomes need to come
from within the discipline, not from
outside it.
Given the suddenness with which
the Human Genome Project burst on
the scene and the hegemony it exerts
over the field, microbiologists did not
have the time or the freedom to
develop an appropriate, overarching
concept for microbial genomics. And
now that microbial genome
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Figure 1
Unrooted phylogenetic tree depicting the
archaeal and eubacterial domains of life.
Figures in brackets indicate the number of
genomes that are either sequenced
completely or for which sequencing is
currently in progress in a given taxon. Taxa
labelled in blue are not represented by any
genome sequence. Of the more than 30
major bacterial taxa now known, more than
20 are not represented by any genome
sequence. Branches without labels represent
environmental rRNA sequences for which
there are no cultivated organisms. The
Archaea are divided into three kingdoms:
Euryarchaeota, Crenarchaeota and
‘Korarchaeota’.
Information is summarized at the following
web sites: The Institute of Genome Research
at http://www.tigr.org/tdb/mdb/mdb.html;
http://www-c.mcs.anl.gov/home/gaasterl/
genomes. (Figure adapted from originals by:
Raju Aravalli, Institute of Molecular Biology,
University of Copenhagen, 1307
Copenhagen, Denmark; Kirk Harris,
Department of Plant and Microbial Biology,
University of California, Berkeley, California
94720–3102, USA.)
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sequencing is under way, it would
seem that many do not feel a need to
develop one. But the need is not
only there, it is critical.
I say all this for one simple
reason: all life turns on microbial life.
The biosphere is largely defined by,
and completely dependent on, the
metabolism of, and interactions
among, microorganisms. The study
of microorganisms is important not
because of the diseases they
produce; to study microbiology is to
study the biosphere. The primary
purpose of microbial genomics has to
be a global understanding of the
microbial world.
Because mankind is stressing the
biosphere, there will soon come a
day when a deep knowledge of the
biosphere and its capacity to adapt
will be critical. Herein lies the
ultimate justification for microbial
genomics and, I believe, the
ultimate justification for genomics
in general.
Microbial genomics has two
main goals: to explore and
understand microbial diversity (the
term used here to include the
interactions among microorganisms
and with their environments); and
to lay bare the ‘evolutionary
dynamic’ (the interplay between
genes that are evolved and inherited
within a given lineage and genes
that have been acquired from other
lineages, the nature of major
evolutionary jumps, and so on). 
The first order of business in
microbial genomics should be a
phylogenetically representative
genomic screen of the microbial
world. In other words, all the major
microbial taxa and their subdivisions
— which are the major source of
biological diversity on Earth —
should be represented by several
genome sequences. There are now
more than 30 recognized major
eubacterial taxa — each the
phylogenetic equivalent of a
eukaryotic kingdom — and at least
half that number in the (far less well
characterized) Archaea; not to
mention the yet-to-be-discovered
kingdoms among the unicellular
eukaryotes.
The fact that there are now more
than 60 eubacterial genomes in the
genome sequencing queue (and
about 10 of them done) might
suggest that we are well on our way
to accomplishing this goal. But look
again. All of these have been chosen
for individual and ‘practical’ reasons.
And so, their phylogenetic
distribution is far from
representative (see Figure 1). The
relatively poor representation of
archaeal genomes and the pathetic
representation of the genomes of
lower eukaryotes in this list
underscores the point. It is essential
that, in the first instance,
phylogenetic considerations dictate
the choice of genomes. Rest assured,
however, that all manner of practical
benefits would also flow naturally
from the kind of concerted program
I have in mind for microbial
genomics — and in some cases they
would come about sooner rather
than later because of the solid
conceptual framework that develops
around an approach of this type.
The second order of business
(second only because it is dependent
on the first) is to sequence those
genomes of value in elucidating the
evolutionary dynamic. The adaptive
nature of our biosphere is a study in
‘horizontal gene transfer’ (the transfer
of genes from one genetic lineage to
another). Major evolutionary jumps
(what evolutionists call
macroevolution) are associated with
major changes in the global
environment. We do not understand
these events and we certainly do not
want to tip global balances.
The above is a vague sketch of a
five-year plan for microbial genomics
— that is all the time that would be
needed to make microbial genomics
a mature field of study. The object is
to generate as much useful
information as possible, as quickly
and as inexpensively as possible.
Using a shotgun sequencing
approach, it is reasonable to expect
that a fairly complete picture of at
least 200 microbial genomes could
be generated within two years and
that the sequences could be refined
and the number of genomes also
extended in the remaining three
years. The cost of this would be
rather less than that of the human
genome and, given the amount of
useful information generated,
reasonable by the standards of
microbiology. The genomic
information would change our
perception of microorganisms, of
microbiology, of the biosphere and
of biology itself. Although such a
program is feasible, it will be
undertaken only if biologists
appreciate its value.
This is not the place to go into
the specifics of which microbial
genomes would be most useful. I
would suggest, however, that a
phylogenetic tree hang on the wall of
every laboratory in which microbial
genomes are being sequenced — for
inspiration.
Address: B103 Chemical and Life Sciences
Laboratory, University of Illinois at Urbana-
Champaign, 601 South Goodwin Avenue,
Urbana, Illinois 61801, USA.
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